|
1. Biologie
|
|
|
|
4.1 Dép., diag. & prono. - Prostate
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
A Painful, Unacceptable Lack of Data [In the Pipeline]
|
|
|
|
|
|
If
you’re going to approve on surrogate endpoints, then make it mandatory
to collect data on what happens afterwards, and set an appropriate date
to review it, with approval to be rescinded if things don’t work out.
Sounds good – but remember what happened when the FDA did that with
Avastin’s breast cancer indication?
|
|
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
5.9.5 IASLC
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
Rethinking cancer, from the basics to the breakthroughs [LA Times]
|
|
|
|
|
|
But
there is this tendency to simplify and exaggerate that progress.
Remember about 18 years ago when the growth-inhibitor drugs —
antiangiogenesis drugs like Avastin — were thought to be the answer to
cancer? A lot of patients got jerked around emotionally and were
promised something that we just didn’t have.
|
|
|
|
|
|
|
|
6.10 Politiques
|
|
|
|
6.12 Ethique
|
|
|
|
6.9 Controverses
|
|
|
|
|
Cancer drug study data was falsified, says AstraZeneca [The Telegraph]
|
|
|
|
|
|
The
journal article was one of dozens of pre-clinical studies showing the
effectiveness of acalabrutinib. AstraZeneca added: “It’s important to
note that this isolated issue had no impact on the integrity of
acalabrutinib data in any clinical trials, and there was no risk to
patient health.”
|
|
|
|
|
|